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Familial hypercholesterolemia (FH) is an autosomal dominant disorder that results in 
elevated levels of low-density lipoprotein cholesterol (LDL-C). This increase in serum cholesterol 
level has been shown to result in premature coronary artery disease (CAD) with devastating 
symptoms from a  young age. Today, the prevalence of heterozygous FH (HeFH) and homozygous 
FH (HoFH) is estimated to be 1 in 320 and 1 in 160,000 people, respectively. FH is referred to as 
an underdiagnosed disease due to the large number of mutations that continues to grow. These 
mutations often exist in one of or a combination of three genes: low-density lipoprotein receptor 
(LDLR), apolipoprotein B (APOB100), or proprotein convertase subtilin/kinase 9 (PCSK9) (S. 
Singh & Bittner, 2015). Mutations in the LDLR adapter protein 1 (LDLRAP1) were also identified 
as a less common cause of FH, the autosomal recessive variety, specifically. In treating the disease, 
patients are prescribed various treatment protocols aimed at reducing endogenous cholesterol 
synthesis, removal of excess cholesterol through extracorporeal machinery, and other medications 
aimed at upregulating the LDL receptors in the body. To this day, liver transplants remain as the 
only cure for FH.  
FH-induced pluripotent stem cells (FH-iPSC) derived from HoFH skin fibroblasts were 
permanently corrected using CRISPR technology to insert the three missing base pairs and restore 
transport of the LDL receptor from the endoplasmic reticulum (ER) to the Golgi body. Hepatocytes 
are the cells primarily responsible for LDL-C uptake from the plasma, so we differentiated non-
corrected familial hypercholesterolemia (NC) and CRISPR-corrected (C) iPSC to hepatocyte-like 
cells (HLC) to analyze restoration of cholesterol homeostasis. iPSC and HLC were treated with 
Rosuvastatin, excess sterols, or tunicamycin and collected for mRNA analysis and protein analysis 
of LDLR and ER stress markers. HLC were also treated with Rosuvastatin and 
  
immunocytochemistry and the Thermofisher Amplex Red Cholesterol Assay kit were used to 
analyze localization of LDLR within the cell and internalization of cholesterol, respectively.  
Statin-treated NC-iPSC and HLC showed predominant expression of an immature LDLR 
protein that was not present in C-iPSC or HLC and this upregulation was not the result of 
regulation at the transcriptional level. The LDLR co-localized to ER resident-protein, Calnexin, in 
NC-HLC whereas the LDLR co-localized to the cell-membrane in the C-HLC. Upon correcting 
expression of the mature LDLR, cholesterol internalization increased overtime in C-HLC in 
contrast to a minimal amount internalized at the 24-hour mark in the NC-HLC. Lastly, statin-
treated NC-iPSC and HLC were not observed to induce ER stress as represented by markers XBP1 
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Familial hypercholesterolemia (FH) is an autosomal dominant disorder that results in 
elevated levels of low-density lipoprotein cholesterol (LDL-C) (Bouhairie & Goldberg, 2015). 
Historically, the prevalence of heterozygous FH (HeFH) and homozygous FH (HoFH) was 
estimated to be 1 in 500 and 1 in one million, respectively, but more recent studies suggest a 
prevalence closer to 1 in 320 and 1 in 160,000 people (de Ferranti et al., 2016; Sjouke et al., 2015). 
These numbers might even be higher, but accurate estimates of FH prevalence are difficult to 
obtain as there is no independent code assigned to this disease by the World Health Organization 
(WHO) (Nordestgaard et al., 2013). Additionally, most countries lack a national FH registry and 
no uniform criteria for FH exists (Akioyamen et al., 2017). It is also referred to as an 
underdiagnosed disease due to the large number of mutations that continues to grow (Soutar & 
Naoumova, 2007). These mutations often exist in one of or a combination of three genes: low-
density lipoprotein receptor (LDLR), apolipoprotein B (APOB100), or proprotein convertase 
subtilin/kinase 9 (PCSK9) (S. Singh & Bittner, 2015). Mutations in the LDLR adapter protein 1 
(LDLRAP1) were also identified as a less common cause of FH, the autosomal recessive variety, 
specifically (Harada-Shiba et al., 1992). 
 
1. Clinical Discovery 
Familial hypercholesterolemia was first described by Norwegian doctor, Carl Müller, in 
the late 1930’s after studying 17 families in Oslo where 68 of 76 members presented with both 
some form of xanthoma and heart disease (Müller, 1939). Xanthomas, depositions of yellow 
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cholesterol-rich material composed of lipids, were first described by Addison and Gull in 1851, 
but the discovery of associated increased levels of cholesterol wouldn’t be made until 1920 by 
Chauffard and Burns (Burns, 1920). Today, the presence of xanthoma accounts for one out of three 
criteria, at least two of which need to be met, in order to diagnose FH (Harada-Shiba et al., 2018). 
Xanthomas have become such a common indicator of FH, that historians are now describing the 
Mona Lisa painting by Leonardo da Vinci as the first case of FH due to the presence of a small 
yellowish nodule at the inner end of her left eyelid as indicated in Figure 1 (Ose, 2008). da Vinci 
was known for his work in atherosclerotic disease so it is possible that his inclusion of this nodule 
was intentional (Keele, 1951). In the 1960’s, Dr. Khachadurian categorized hypercholesterolemia 
into three categories – homozygous FH, heterozygous dominant FH, and heterozygous recessive 
FH – after analyzing a number of Lebanese families and describing the codominant inheritance of 




Figure 1 – A small yellowish nodule present on the inner eyelid of the Mona Lisa by Leonardo da Vinci (Kuzaj, 
Kuhn, Faust, Knabbe, & Hendig, 2014) 
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2. The Low-Density Lipoprotein Receptor 
The low-density lipoprotein receptors (LDLRs or LDL receptors) in hepatocytes act as the 
primary method of cholesterol removal from plasma through receptor-mediated endocytosis. The 
LDL receptor is a transmembrane protein with 5 domains as represented in Figure 2 below: LDLR 
repeat domain, EGF repeat domain, O-linked glycosylation domain, transmembrane domain, and 
cytoplasmic domain (Jain, Jain, Kesharwani, & Jain, 2013; Lagor & Millar, 2009). The LDLR 
repeat domain is responsible for ligand binding, specifically apolipoprotein B100 (ApoB100) on 
LDL and ApoE. The epidermal growth factor (EGF) repeat domain consists of three repeated 
sequences. The first of these two domains are linked to the third by a sub-domain of 6 short amino 
acid repeats to form a six-bladed b-propeller. This b-propeller interacts with the LDLR repeat 
domain and contributes to ligand release from the receptor after internalization has occurred. The 
O-linked sugars on the O-linked glycosylation domain are thought to prevent proteolytic cleavage 
of the extracellular domain while it sits on the plasma membrane. Mutations in this domain have 
shown no effect on ligand binding. The transmembrane domain anchors the LDLR to the plasma 
membrane. Finally, the cytoplasmic domain contains a glycine that is required for proper sorting 





Figure 2 – The five domains of the low-density lipoprotein (LDL) receptor (Jain et al., 2013) 
 
3. Sources of Cholesterol  
FH is a disorder characterized by disruption in LDL-C metabolism and so it is important 
to briefly review this pathway and that of cholesterol synthesis. All of the cholesterol present in 
the human body arises from one of two sources: ingestion of cholesterol-containing foods or de 
novo synthesis within cells (Cerqueira et al., 2016). 
Dietary Cholesterol.  The human body absorbs more than 95% of ingested fatty acid and 
monoacylglycerols (Pan & Hussain, 2012). Once ingested, dietary cholesterol is formed into 
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micelles by bile salt activity and presented to mucosal enterocytes in the intestine (Lu, Lee, & 
Patel, 2001). Upon absorption into enterocytes in the jejunum of the small intestine, free 
cholesterol and fatty acids are re-esterified by acyl-coenzyme A:cholesterol acyl-transferase and 
packaged into chylomicrons with triglycerides, phospholipids, and apolipoprotein B-48 (Dawson 
& Rudel, 1999). Chylomicrons transport lipids absorbed in the intestine to adipose, cardiac, and 
muscle tissue where lipoprotein lipase (LPL) hydrolyzes the triglyceride component (Dash, Xiao, 
Morgantini, & Lewis, 2015). Chylomicrons are secreted from the basolateral aspect of the 
enterocytes into the lymphatic channels and reaches the liver where it can be packaged into 
lipoproteins and secreted into the plasma or secreted into bile (Crawford et al., 1997).  
Endogenous Cholesterol Synthesis.  There are approximately 45 steps that take place in 
cholesterol biosynthesis as summarized in Figure 3. The first of which begins with the enzyme 
thiolase catalyzing the reaction to form acetoacetyl-CoA from two acetyl-coenzyme A (acetyl-
CoA) molecules. Next, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase catalyzes the 
reaction to form HMG-CoA from acetoacetyl-CoA and another molecule of acetyl-CoA. Next, 
HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, catalyzes the NADP-
dependent synthesis of mevalonate from HMG-CoA. Inhibiting HMG-CoA reductase is a common 
target for pharmaceutical drugs for FH in order to decrease the amount of endogenously produced 
cholesterol. Once mevalonate is synthesized, it is converted into two activated isoprenes, 
isopentanyl 5-pyrophosphate and dimethylallyl pyrophosphate, before a series of condensations of 
activated isoprenes take place to form a 30-carbon molecule called squalene, the biochemical 
precursor of all steroids. It has to be converted to lanosterol, which is then transformed into 
cholesterol after a number of reactions. Cholesterol that exceeds the needs of the cell is transported 
through the blood as very low-density lipoprotein (vLDL) (Berg, 2002). These particles are either 
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taken up by the liver for processing or converted into low-density lipoprotein (LDL). LDL delivers 
cholesterol throughout the body for use in cell membranes, hormone production, Vitamin D 
production, and bile acid synthesis (Cortes et al., 2014).  
 7 
 
Figure 3 – Cholesterol synthesis 
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4. Receptor-Mediated Endocytosis 
In receptor-mediated endocytosis, a specific receptor on the cell surface binds to the 
extracellular molecule of interest before it undergoes endocytosis and becomes a transport vesicle 
for further processing within the cell (Lodish, 2000). LDL, as mentioned earlier, has a large protein 
called ApoB100. ApoB100 is what is recognized by the LDL receptor in order to bind the LDL 
particle (Brown & Goldstein, 1979). Once the LDL particle is bound, the LDL receptor clusters 
into a clathrin-coated pit that encloses the LDL receptor and begins to form a coated endocytic 
vesicle. Next, this vesicle detaches from the membrane to carry the LDL into the cell where it’s 
taken into a lysosome. Once inside the lysosome, the LDL receptor detaches from the LDL particle 
and is recycled back to the cell surface. The LDL particle remains inside the lysosome and is 
degraded. When LDL receptors are no longer needed, PCSK9 binds to the EGF-A repeat domain 
on the LDLR to mark it for degradation by lysosomes. Mutations in the APOB100, LDLR, or 
PCSK9 genes will disrupt this pathway and can result in increased levels of LDL-C. This process 
is summarized in Figure 4.  
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Figure 4 – LDLR pathway 
 
5. Mutations in Cholesterol Metabolism 
With respect to FH, mutations in the PCSK9 gene are gain-of-function mutations that 
increase the degradation of the LDL receptor and in turn decrease LDL-C uptake, leaving it to 
circulate within the body (Sharifi, Futema, Nair, & Humphries, 2017). Pharmaceutical drugs that 
inhibit PCSK9 synthesis are also common in certain types of FH with the goal of decreasing LDLR 
degradation by PCSK9 in order to increase LDL-C uptake. Loss-of-function mutations within the 
PCSK9 gene also exist, but do not lead to FH as they decrease the degradation of LDL receptors 
which in turn decreases the amount of LDL-C in the body and results in a 28% lower risk of 
coronary heart disease (Benn, Nordestgaard, Grande, Schnohr, & Tybjaerg-Hansen, 2010). 
Mutations in the APOB100 gene that cause FH are due to missense mutations that result in a 
ligand-defective ApoB100 protein. This renders the LDL-C particle unable to bind to the LDL 
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receptor and in turn continues to circulate in the blood (Myant, 1993). Mutations in the LDLR, the 
most common FH-causing mutations, are loss-of-function mutations. As of 2017, there are more 
than 2,600 mutations in the LDLR gene that cause FH, all of which can be categorized into one of 
five classes of mutations as summarized in Table 1 (H H Hobbs, D W Russell, M S Brown, & 
Goldstein, 1990).  
 
TABLE 1 
CLASSES OF LDLR MUTATIONS 
Classification Mutation 
Class I LDLR is not synthesized 
Class II LDLR not properly transported from ER to Golgi apparatus 
Class III LDLR unable to properly bind LDL on cell surface 
Class IV LDLR bound to LDL unable to be internalized 
Class V LDLR is not recycled to cell surface 
 
Class I mutations result in no synthesis of the LDL receptor. Class II mutations disrupt the transport 
of the receptor due to improper folding that prevents them from meeting the criteria needed to exit 
the ER and travel to the Golgi body for further modification. The mutation in the cells of this study 
is characterized as a Class II mutation. Class III mutations affect the binding of the LDL to the 
receptor. Class IV mutations prevent the internalization of the receptor once it has bound an LDL 
particle. Finally, Class V mutations prevent receptors from being recycled to the plasma membrane 
and leave them to be degraded along with the LDL particle in the lysosome upon initial 
internalization.  
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Heterozygous FH (HeFH) is caused by inheriting one mutated allele and one normal allele. 
This is the most common type of FH and results in LDL-C levels in the 350-550 mg/dL range, a 
200% increase of normal LDL-C levels that range from 100-190 mg/dL (Pejic, 2014). 
Homozygous FH (HoFH), the more devastating type, is caused by inheriting two mutated alleles. 
This results in LDL-C levels in the 650-1,000 mg/dL range, a 500% increase over normal levels. 
Within these categories exist sub-types that further characterize the type of FH a person has. In 
true homozygous FH, the same mutation is observed in both alleles. This type is less common than 
compound heterozygous FH, different mutations are observed in each allele of the same gene, or 
double heterozygous FH, mutations in two different genes affect the LDLR function (Cuchel et 
al., 2014). Elevated levels of LDL-C, as early as the fetus, as a result of these mutations result in 
accelerated levels of cholesterol deposition and development of atherosclerosis (Brown & 
Goldstein, 1986; Buja, Kovanen, & Bilheimer, 1979). The development of atherosclerosis will 
often lead to premature coronary heart disease (CHD) in men and women by ages 50 and 60, 
respectively (Hopkins, Toth, Ballantyne, & Rader, 2011). It is estimated that 5% of myocardial 
infarctions (MIs) in patients <60 years and 20% of MIs in patients <45 years are a result of FH. 
HoFH patients, untreated, will develop overt atherosclerosis before the age of 20 and typically 
don’t survive past age 30 (Goldstein & Brown, 2001).  
 
6. Endoplasmic Reticulum Stress 
 The endoplasmic reticulum (ER) is the organelle where protein folding occurs for proteins 
destined for intracellular organelles and the cell surface (Kaufman, 2004). There are a number of 
cell signaling pathways that regulate mRNA translation and prevent accumulation of unfolded 
protein by decreasing the load, increasing the folding capacity, and increasing the degradation of 
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misfolded proteins. Before exiting the ER to be transported elsewhere, proteins are sorted to 
determine if a protein is properly folded and is able to leave the ER. Otherwise retention signals 
are sent to prohibit the protein from exiting and eventually degrading the misfolded protein 
(Ellgaard & Helenius, 2003). This retention in the ER also extends the amount of time a protein is 
exposed to the folding machinery and increases the chance of correct and proper folding. The 
protein concentration in the ER lumen is relatively high, 100 mg/mL, requiring protein chaperones 
to facilitate the folding process to prevent aggregation that could cause ER stress and activate the 
unfolded protein response. These protein chaperones and folding sensors include BiP, calnexin, 
calreticulin, glucose-regulated protein (GRP)94, thiol-disulphide oxidoreductases protein 
disulphide isomerase (PDI), and ERp57 ("Calnexin, calreticulin and the folding of glycoproteins," 
1997; Fra, Fagioli, Finazzi, Sitia, & Alberini, 1993; Hellman, Vanhove, Lejeune, Stevens, & 
Hendershot, 1999).  
 Three branches of the UPR have been identified and work in parallel to increase folding 
capacity, decrease folding load, or degrade accumulated protein to allow the cell to restore 
homeostasis or apoptose ((Ron & Walter, 2007). The three signal transducers are activating 
transcription factor 6 (ATF6), double-stranded RNA-activated protein kinase (PKR)-like ER 
kinase (PERK), and inositol requiring enzyme 1 (IRE1). Their pathways have been summarized 
in Figure 5 and will be discussed here briefly. The first transducer, ATF6, is a transcription factor  
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Figure 5 – Three pathways of the unfolded protein response (Ron & Walter, 2007).  
 
that is packaged into vesicles and transported to the Golgi apparatus upon protein accumulation 
(Schindler & Schekman, 2009). ATF6 encounters two proteases that remove the luminal domain 
to allow the liberated N-terminal cytosolic fragment to move to the nucleus and activate UPR 
target genes including BiP. ATF6 increases the folding capacity of the ER. The second transducer, 
PERK, oligomerizes and phosphorylates itself when sensing ER stress. It also phosphorylates the 
ubiquitous translation initiation factor eIF2a which inactivates eIF2 and inhibits mRNA 
translation. Some mRNAs that contain short open reading frames are preferentially translated and 
encode the ATF4 transcription factor and induces its translation. ATF4 targets CCAAT-enhancer-
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binding protein homologous protein (CHOP) and growth arrest and DNA damage-inducible 34 
(GADD34). CHOP controls genes involved in apoptosis and so the PERK pathway also 
contributes to signaling cell-death. PERK reduces the flux of protein entering the ER to reduce 
folding load. Lastly, the IRE1 pathway uses mRNA splicing to transmit the UPR signal. It becomes 
activated by conformational changes after lateral IRE1 oligomerization in the ER membrane. Upon 
activation, IRE1 cleaves the mRNA encoding the UPR-specific transcription factor, X-box binding 
protein 1 (XBP1) and the severed exons are then ligated and result in spliced XBP1. IRE1 pathway 
is also responsible for reducing the folding load in the ER.  
 Little research has been published about ER stress specific to HoFH. Jorgensen et al. 
showed the molecular chaperone BiP co-immunoprecipitates with both wild type and two different 
mutant LDL receptors in lysates from human liver cells that overexpressed wild type or mutant 
LDL receptors. They concluded that BiP was co-immunoprecipitated with the mutant receptors 
five times more than the wild type receptors suggesting that BiP is involved in the retention mutant 
LDL receptors in the ER (Jorgensen et al., 2000). In Sorensen et al., Chinese hamster ovary (CHO) 
cells were transfected with mutant LDLR and showed increase in the activity of IRE1 and PERK 
concluding that retention of the mutant LDLR in the ER induces ER stress.  
 
7. Current Treatment 
In patients with FH, the primary goal of treatment is the management and prevention of 
further atherosclerotic coronary artery disease through control of cholesterol levels as there 
continues to be no cure beyond liver transplantation for FH. These treatments include lifestyle 
changes, drugs that target PCSK9, HMG-CoA reductase, or dietary cholesterol absorption, bile-
acid sequestrants, lipid apheresis, liver transplants, and gene therapies (Lambert et al., 2014). 
 15 
Lifestyle changes include avoiding smoking, participating in regular physical activity, and 
following dietary recommendations. Patients are told to follow a fat-reduced diet which provides 
25-35% of total caloric intake, saturated fats less than 7% of total caloric intake, less than 200 mg 
of cholesterol per day, increased intake of monosaturated and polyunsaturated fats and fiber, and 
plant sterols, 2 mg daily. Statins are a competitive inhibitor of HMG-CoA reductase and will work 
to block cholesterol synthesis in the liver and in turn decrease LDL production. They are the first 
line of pharmacologic agents used in treating FH and are recommended for use to reduce LDL-C 
by at least 50% from baseline. Even with aggressive statin therapy, the majority of FH patients 
don’t reach more than a 50% reduction in LDL-C and are recommended to incorporate cholesterol 
absorbing inhibitors as well. Cholesterol absorption inhibitors block the absorption of dietary 
cholesterol and delivery of intestinal cholesterol to the liver. This leads to an up-regulation in LDL 
receptors on hepatocytes and increased uptake of LDL-C. This treatment was found to decrease 
LDL-C levels by an additional 15% when used in conjunction with statin treatments (Stein et al., 
2007).  
Bile acid sequestrants (BASs) have also been shown to lower LDL-C levels. Bile acids are 
digestive surfactants that promote the absorption of lipids by acting as emulsifiers (Staels & 
Fonseca, 2009). When a meal is ingested, the gallbladder contracts and releases bile acids into the 
intestinal lumen to aid in this ingestion. Enterohepatic circulation allows for 95% of bile acids to 
be reabsorbed and transported back into the liver. Bile acid sequestrants work by binding 
negatively charged bile acids in the intestinal lumen to divert the bile acids from enterohepatic 
cycling and instead into the feces for excretion (Insull, 2006). This prevents bile acids from cycling 
and aiding in the absorption of LDL-C. BASs were originally the first treatment for FH, but are 
now used as a 2nd or 3rd line of treatment after statins. Another recommended treatment for FH is 
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through inhibiting PCSK9. PCSK9, as mentioned earlier, is responsible for premature LDL 
receptor degradation. Inhibiting PCSK9 would result in increased levels of LDL receptors and 
increased uptake in LDL-C. PCSK9 inhibitors are injectable monoclonal antibodies that bind to 
PCSK9 to prevent their degradation of LDLRs. The ability of anti-PCSK9 therapies to 
significantly lower LDL-C levels have enabled the frequency of other treatments, such as lipid 
apheresis to be markedly reduced (Ogura, 2018). Lipid apheresis removes circulating LDL by 
removing blood from a vein, separating it into cellular and plasma components, removing LDL, 
and returning the blood to the patient. There are methods that don’t involve separation of plasma 
and cells, direct lipoprotein adsorption, where polyacrylamide beads with pores that only allow 
certain particles, such as LDL, to enter and be removed. Lipid apheresis imposes a great burden 
on the patient in the form of high costs per treatment, high frequency of treatments needed, and 
long time to complete each treatment, 3-5 hours. Many patients drop out of therapy as a result of 
the physical or financial problems related to it. In HeFH patients, these treatments often work well 
in order to achieve relatively, more normal LDL-C levels, at least a 50% reduction. In HoFH 
patients, these treatments are aimed at lowering cholesterol levels in order to avoid a liver 
transplant.  
Liver transplants remain the only option for HoFH patients that don’t respond to 
pharmacological agents. They replace the dysfunctional hepatic LDL receptors to allow the patient 
to reach near normal levels of LDL-C through normal metabolism. The long-term outcomes are 
unknown due to a number of factors. There are limited organ donors, need for life-long 
immunosuppressive therapy, and a high risk in post-operational outcomes. However, recent data 
has shown the five-year survival rate after liver transplants to near 90% in pediatric patients 
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(Kusters et al., 2010). With liver transplants as the only cure for HoFH patients, gene therapies 
have been explored as an alternate treatment option.  
The goal of gene therapy is to deliver a functional LDLR transgene to the liver. In 1995, 
Grossman et al. performed the first gene therapy clinical train in HoFH patients with little success 
(Grossman et al., 1995). An ex vivo approach was used to transfer replication-deficient human 
LDLR-expressing retroviruses into the liver. The patients first underwent resection of the hepatic 
left-lateral segment, their hepatocytes were harvested, transduced ex vivo using the retrovirus 
vector, and then infused back into the donors through the portal vein. Only few transduced 
hepatocytes were observed and the reduction in LDL-C levels varied between 6-25%. These 
findings confirmed the feasibility of LDLR gene therapy in humans, but required further work in 
order to be successfully implemented. Recently, a recombinant adeno-associated virus (AAV) 
vector has entered clinical testing as the most developed form of gene therapy (Ajufo & Cuchel, 
2016). AAV is a replication-defective, non-pathogenic parvovirus that retains its DNA in the host 
cell nucleus in a circular episomal form allowing for stable gene expression in post-mitotic tissue. 
The first AAV vector developed achieved efficient gene transfer and stable hepatocyte 
transduction, but expressed poor liver tropism in humans. Multiple different AAV vectors have 
been developed that differ in tropism and immunogenicity to allow for broader use in gene therapy. 
Most recently, AAV8 was used for liver-directed gene therapy in HoFH and compared well in 
relation to the earlier vectors AAV2 and AAV7. AAV8 was associated with more efficient gene 
transfer, hepatocyte transduction, and more complete lipid correction.  
 
8. Cell Therapy  
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 Cell therapy has emerged as a plausible alternative to many treatments used for liver 
diseases. Cells serve as an effective and favorable treatment due to their ability to work together 
to perform complex functions and have behavior that can be specifically engineered based on the 
desired need (Fischbach, Bluestone, & Lim, 2013). Cell therapy can be categorized based on a 
number of groups – method of delivery, cell line, cell source, and cell in vivo half-life – all of 
which are summarized in Table 2 (Bhatia, Underhill, Zaret, & Fox, 2014; Culme-Seymour, Davie, 
Brindley, Edwards-Parton, & Mason, 2012; Nicolas, Wang, & Nyberg, 2016). The use of induced 
pluripotent stem cells (iPSC) has emerged as an attractive branch of cell therapy. In 2006, 
Takahashi and Yamanaka reprogrammed somatic cells into iPSC using four reprogramming 
factors, Octamer binding transcription factor-4 (Oct4), Sex determining region Y – box 2 (Sox2), 
Kruppel Like Factor-4 (Klf4), and c-MYC (Takahashi & Yamanaka, 2006). They were 
demonstrated to be both self-renewing and able to differentiate like embryonic stem cells (ESC) 
and could provide an alternative to ESC to overcome ethical concerns.  
 Since their discovery, iPSC have been used in a number of applications including disease 
modeling, regenerative medicine, and drug discovery and cytotoxicity tests (V. K. Singh, Kalsan, 
Kumar, Saini, & Chandra, 2015). iPSC technology offers a number of advantages. iPSC are similar 
in their abilities to ESC and can be generated without using fertilized embryos, in turn overcoming 
ethical concerns associated with the use of ESC. They also present reduced chances of 
immunorejection. By using patient-derived cells and reprogramming them to iPSC before 
differentiation to another type of cell, the chances of immunorejection are reduced. This was also 
shown by Guha et al. who showed no evidence of increased T cell proliferation or an antigen-
specific secondary immune response after transplanting iPSC derived embryonic bodies or tissue-
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specific cells (Guha, Morgan, Mostoslavsky, Rodrigues, & Boyd, 2013). iPSC also provide a 
canvas for testing toxicity and therapeutic effect of newly developed drugs.  
 
TABLE 2 
CELL THERAPY CATEGORIES 
Method of Delivery 
Cell Transplantation Injection of whole cells 
Bioartificial Organs 
Whole cells in extracorporeal 
devices 
Cell Line 
Primary Cell Mature parenchymal cells 
Stem Cells Tissue-derived stem cells 
Cell Source 
Allogenic Human donor 
Autologous Self donor 
Xenogeneic Animal donor 
Cell in vivo Half-Life 
Transient dosing Days or weeks 





B. Previous Work 
The aim of this study was to characterize the LDL receptor in CRISPR-corrected HLC 
derived from skin fibroblasts of HoFH patients. Our lab has previously shown the ability to restore 
LDL receptor-mediated endocytosis in HoFH-iPSC in Ramakrishnan et. al (Ramakrishnan et al., 
2015). NC-iPSC were generated from FH fibroblasts and differentiated towards a hepatic lineage 
through a five-stage process. At the end of the fifth stage, almost 90% of cells were expression 
alpha fetoprotein (AFP), a major plasma protein produced by the yolk sac and fetal liver during 
development, and albumin, a protein made by the liver (Ramakrishnan et al., 2015). FH-iPSC were 
transfected with a pEHZ-LDLR-LDLR plasmid containing a wild-type LDLR and differentiated 
into mesenchymal cells. Upon treatment with excess sterols, cells showed little internalization of 
1,1’-dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate (DiI-LDL), but a 2-fold 
increase in internalization with statin treatment.  
In Omer et al., 3040 induced pluripotent stem cells (iPSC) were corrected using CRISPR 
(Omer et al., 2017). The parental GM03040 skin fibroblasts were reprogrammed to 3040-iPSC 
using a synthetic messenger RNA cocktail containing octamer-binding transcription factor 4 
(OCT4), sex determining region Y-box (SOX2), Kruppel-like factor 4 (KLF4), c-mycproto-
oncogene (C-MYC), and Lin-28 homolog A (LIN-28). The mutation of this specific HoFH patient 
was a Class II mutation due to a 3 base pair deletion (ACC) on exon 4 of the LDLR sequence. This 
mutation resulted in little to no LDL receptor-mediated LDL uptake due to misfolding of the LDLR 
protein. In order to correct the mutation, CRISPR was used to insert the missing 3 base pairs. The 
3040-iPSC were transfected with Cas9 nickase (Cas9n) modified to incorporate green fluorescent 
protein (GFP), single-guide RNA 1 plasmids (sgRNA1) containing a red fluorescent protein 
(RFP), and single-stranded oligodeoxynucleotide (ssODN) and cells were sorted for dual-positive 
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expression (GFP and RFP) for further cell culture. Correction was also confirmed by restriction 
fragment length polymorphism (RFLP) by using the novel XmnI restriction site that was 
introduced with the donor repair template. Sanger sequencing was also used in order to confirm 
the presence of the previously-deleted 3 base pairs.  
The corrected 3040-iPSC, non-corrected 3040-iPSC, and human embryonic stem cells 
(H1) were differentiated to hepatocyte-like cells (HLC) and treated with lovastatin, excess sterols, 
and low-density lipoprotein labeled with DiI-LDL to observe the effect of the correction. As 
expected, the lovastatin treatment resulted in induction of the LDLR in all three cells lines, but 
was primarily present in its immature form in the non-corrected 3040-iPSC with little mature 
protein present. The corrected 3040-iPSC expressed predominantly mature LDLR protein which 
further confirmed the correction had occurred and responded normally to statin treatment. The 
excess sterol treatment resulted in a down-regulation of LDLR expression across all cell lines 
suggesting regain of function of the LDLR in the corrected cells. DiI-LDL treatment was used to 
visualize the internalization of LDL. DiI-LDL depends on receptor-mediated endocytosis in order 
to be internalized into the cell, but it is important to note here that after a sufficient period of time, 
it can be internalized by the cell through non-receptor mediated pathways such as pinocytosis. The 
internalization of DiI-LDL by the corrected 3040-iPSC was similar to that of the control H1 cells 
whereas there was very little to no internalization by the non-corrected cells. Following this work, 
there still remained a number of questions regarding the cholesterol metabolism in the corrected 





 We hypothesized that a Class II LDLR mutation disrupts cholesterol homeostasis and 
induces ER stress and will be alleviated by correction of the LDLR. We aimed to determine the 
level of restoration of cholesterol metabolism and homeostasis in FH Class II mutant patient-
derived cells after CRISPR correction. This was achieved by looking at key steps of cholesterol 
metabolism including the expression of the mature LDL receptor, the internalization of 
exogenously-introduced LDL, and HMG-CoA reductase activity.  
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II. PROCEDURE 
A. Differentiation of Induced Pluripotent Stem Cells (iPSC) to Hepatocyte-Like Cells (HLC) 
 A protocol adapted from Hay et al. was used to differentiate induced pluripotent stem cells 
(iPSC) to hepatocyte-like cells (HLC) (Hay, Fletcher, et al., 2008; Hay, Zhao, et al., 2008). 
Familial hypercholesterolemia cells (NC) iPSC, CRISPR-corrected familial hypercholesterolemia 
(C) iPSC, and human embryonic stem cells (H1) (WiCell, Madison, WI) were cultured on hESC-
Qualified Matrigel coated 35 mm tissue culture plates (BD Bioscience, San Jose, CA) in mTeSR1 
(STEMCELL Technologies, Vancouver, Canada) in an incubator maintained at 5% CO2 and 37°C. 
Upon reaching 70% confluency, cells were passaged using Versene (Thermo Fisher, Waltham, 
Ma) with 10 mM Rock inhibitor (Selleck Chemical, Houston, TX) into appropriately-sized tissue 
culture dishes as required by each experiment and allowed to grow. Differentiation commenced 




Figure 6 – Differentiation timeline 
 
Cells were first differentiated to definitive endoderm in stage one. Stage one lasted five days and 
required daily media changes with fresh additions of Activin A [100 ng/mL] (Peprotech, Rocky 
Hill, NJ) and Wnt3a [50 ng/mL] (R&D Systems, Minneapolis, MN) in RPMI 1640 media 
(Invitrogen, Waltham, MA) with 1X B27 (Invitrogen). After five days of stage one, cells were 
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switched to stage two media requiring media changes every 48 hours for five days for the 
hepatoblast stage. Stage two media consisted of knockout Dulbecco’s modified Eagle’s medium 
(KO-DMEM) media (Invitrogen) supplemented with 20% knock-out serum replacement 
(Invitrogen), 0.5X GlutaMAX (Invitrogen), 1X nonessential amino acids (NEAA) (Invitrogen), 
0.1 mM 2-mercaptoethanol (Thermo Fisher), and 1% (v/v) dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, St. Louis, MO). Finally, stage three, hepatocyte-like cell stage, required media changes 
every 48 hours for a maximum of 11 days. Stage three media consisted of HepatoZYME media 
(Invitrogen) supplemented with 0.5X GlutaMAX, 10 µM Hydrocorstisone-21 (Sigma-Aldrich), 
and hepatocyte growth factor (HGF) [10 ng/mL] (Peprotech) and Oncostatin M (OSM) [20 ng/mL] 
(Peptrotech) added fresh.  
 
B. LDLR Protein Expression in Statin-Treated iPSC and HLC 
1. Cell Treatment  
Non-corrected, corrected, and H1 iPSC or HLC were treated overnight with 5 µM 
Rosuvastatin (EMD Millipore, Burlington, MA) or excess sterols (10 µg/mL cholesterol and 5 
µg/mL 25-Hydroxycholesterol) (Sigma-Aldrich) in 5% lipoprotein-deficient serum media 
(LPDS) (Alfa Aesar, Tewksbury, MA). Control cells were treated with DMSO overnight. iPSC 
were used in experiments in order to look at how these cells might be affected by statin treatment 
as a way to replicate conditions experienced by pregnant women prescribed statins. HLC were 
used in experiments in order to look at how our correction affected cells differentiated to a 
mature hepatocyte-like stage. As described earlier, statins are an HMG-CoA Reductase inhibitor, 
the rate-limiting enzyme in cholesterol synthesis, and should result in upregulation of the LDLR 
in order to obtain cholesterol from an external source, the cell culture media in this case. Excess 
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sterols were used as a control to determine the functionality of our cells. Excess sterols are 
internalized by the cell through non-receptor mediated pathways and, as a result, downregulate 
the LDLR because the cholesterol needs of the cell have been met.  
2. Cell Collection 
Cells were washed twice with ice-cold phosphate buffered saline containing magnesium 
and calcium (PBS +/+) then scraped and collected in additional ice-cold PBS +/+. Collected 
samples were centrifuged (200 x g, 4 minutes) and pellets were resuspended in RIPA lysis buffer 
(Thermo Fisher), containing [1:100] protease and phosphatase inhibitor cocktail (Thermo 
Fisher), and lysed overnight at 4°C. The next day, cell lysates were centrifuged (13,000 x g, 10 
minutes) and supernatants were transferred to new tubes to measure protein concentration using 
DC Protein Assay (Bio-Rad).  
 
C. LDLR mRNA Expression in Statin-Treated iPSC and HLC 
1. Cell Treatment  
Non-corrected, corrected, and H1 iPSC or HLC were treated overnight with 5 µM 
Rosuvastatin or excess sterols in 5% lipoprotein-deficient serum media (LPDS) (Alfa Aesar, 
Tweksbury, MA). Control cells were treated with DMSO overnight.  
2. Cell Collection and Sample Preparation 
 Cells were lysed using 150 µL of RLT Buffer (Qiagen, Valencia, CA) with 0.1% b-
mercaptoethanol. Lysates were purified with QIAshredder and RNeasy kits (Qiagen) per kit 
instructions. RNA was quantified with a NanoDrop One Spectrophotometer (Thermo Fisher). 
Next, cDNA was synthesized using 1 µg RNA with SuperScript IV reverse transcriptase 
(Invitrogen) in a 20 µL volume. Finally, qPCR was performed using Fast SYBR Green Master 
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Mix (Thermo Fisher) with appropriate primers for the LDLR (Integrated DNA Technologies) as 
listed in the Appendix. Reactions were run on the StepOnePlus Real-Time PCR System (Thermo 
Fisher). 
 
D. Localizing LDLR in HLC 
1. Cell Treatment 
 Non-corrected and corrected HLC were plates in 4 wells of a 4-well chamber slide and 
differentiated as described above. Following differentiation, cells were treated with Rosuvastatin 
in LPDS overnight before preparing for imaging.  
2. Preparation for Imaging 
Cells were fixed with 2% paraformaldehyde (PFA) in PBS (10 minutes, 24°C) after. Next, 
cells were permeabilized with 0.05% Triton X-100/PBS (10 minutes, 24°C) (Sigma Aldrich) and 
washed with PBS. Cells were then blocked with 5% normal donkey serum/PBS (Jackson 
ImmunoResearch) for 1 hour before blocking with an avidin/biotin blocking kit (Vector 
Laboratories). Primary antibodies, calnexin (EMD Millipore, Billerica, MA) and biotinlated-wheat 
germ agglutinin (Vector Laboratories), were diluted in 5% donkey serum/PBS and incubated on 
cells overnight at 4°C. Secondary antibodies were also diluted (1:1000) in 5% donkey serum/PBS 
and added to the cells (2 hours, 24°C) before washing and mounting with VECTASHIELD 
Antifade Mounting Medium with DAPI. Slides were imaged with Olympus BX61W1 confocal 
microscope with Fluoview (FV10-ASW 4.1, Olympus) and analyzed with AMIRA software 
(Thermofisher). A list of antibodies used is available in the appendix. 
3. Quantifying Colocalization 
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 Fluoview (FB10-ASW 4.1) was used to analyze colocalization by using the colocalization 
tool under the processing tab to quantify overlap between selected channels and provide a visual 
representation of the overlap. To quantify images using the software, load the image and click on 
the “Processing” tab in the toolbar at the top of the page and select “Colocalization”. In the 
command window that appears, choose “Series” to analyze the full stack. Under the “Axis” 
options, choose the channels of interest for quantification (e.g. LDLR and Calnexin, LDLR and 
WGA). Under “Annotated Methods” select “Threshold” to provide a threshold value, above which 
the overlap will be considered. A value of 500 was used to begin when setting up with IgG controls, 
after the numbers given by the IgG control images were used as threshold values for the remaining 
images. Reselect the channels under “Axis” to update the statistics then click on “Statistics” 
located in the bottom corner of the command window. This provided values of overlap between 
channels. The overlap data provided a number representing the colocalization of a pixel from each 
channel throughout the entire stack. This also provided an image with the overlap between two 
channels pseudo colored to default white, we changed it to yellow for better visualization.  
 
E. Cholesterol Internalization in HLC – Amplex Red Kit 
1. Cell Treatment 
 Non-corrected and corrected cells were plated on 35 mm tissue culture dishes and 
differentiated until day one of stage three, as described above. On day two and three of stage three, 
media was replaced with lipoprotein-deficient serum (LPDS) media supplemented with 5 µM 
Rosuvastatin and cells were incubated overnight. The following day, cells were treated with LPDS 
media supplemented with 5 µM Rosuvastatin and 10 mM methyl-b-cyclodextrin (Sigma-Aldrich) 
for 45 minutes. Timepoint zero was collected after this treatment and the remaining culture dishes 
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were treated with LPDS media supplemented with 5 µM Rosuvastatin and 10 µg/mL unlabeled 
low-density lipoprotein (LDL). Cells were collected at six and 24 hours.  
2. Cell Collection 
 Cells were collected by incubating in TrypLE Express (Thermo Fisher) for five minutes 
then gently scraped and transferred to 15 mL tubes and centrifuged (200 x g, 4 minutes). The pellet 
was resuspended in a 200 µL chloroform/methanol (2:1 v/v) mixture, vortexed, and centrifuged 
(14,000 x g, 5 minutes) to allow separation into three layers. A micropipette was used to carefully 
discard the top layer. Next, a micropipette was used to gently push past the middle layer (a thin 
membrane) and transfer the bottom layer to new microcentrifuge tubes. These microcentrifuge 
tubes were dried using a vacuum for 30 minutes using a Savant SpeedVac Vacuum. The dried 
lipids were resuspended in 1X reaction buffer from the Amplex Red Cholesterol Assay Kit 
(Thermo Fisher). The middle layer was resuspended in RIPA lysis buffer and lysed overnight at 
4°C. Cell lysates were centrifuged the next day (13,000 x g, 10 minutes) and supernatants were 
transferred to new microcentrifuge tubes and used for protein analysis using DC protein assay 
(Bio-Rad).  
3. Lipid Analysis and Normalization 
 Collected lipid content was analyzed using the Thermo Fisher Amplex Red Cholesterol 
Assay Kit per the instructions. Briefly, a 5.17 mM cholesterol reference was diluted in 1X reaction 
buffer to create a standard curve ranging from 0 to 20 µM. The lipids collected from the cells, see 
section D.2 above, were pipetted in triplicates in a 96-well plate. A working solution was made by 
mixing Amplex Red reagent, HRP, cholesterol oxidase, cholesterol esterase, and 1X reaction 
buffer (concentrations as indicated by the kit instructions). Reaction samples were analyzed with 
an excitation of 560 nm and emission detection at 590 nm in a spectrophotometer. Lipid content 
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was normalized to total protein level as measured by the DC protein assay (Bio-Rad). Briefly, a 
standard curve was made using 1 mg/mL bovine serum albumin (BSA) and 0.9% NaCl solution 
as outlined in the table below.  
 
TABLE 3 
BSA STANDARD CURVE 
Standard Tube Final [C] (µg) BSA (µL) NaCl (µL) 
0.0 (blank) 0.0 50.0 
1.0 5.0 45.0 
2.5 12.5 37.5 
5.0 25.0 25.0 
7.5 37.5 12.5 
 
Each standard was mixed with RIPA lysis buffer at a 1:1 ratio. 10 µL of sample was transferred to 
a new labeled microcentrifuge tube and 10 µL of NaCl solution was added. Standards and samples 
were pipetted in triplicates into a 96-well plate. Reagent A’ was made by adding 20 µL of Protein 
Assay Reagent S to 980 µL Protein Assay Reagent A and vortex-mixed. 25 µL of Reagent A’ was 
added to each well followed by 200 µL of Protein Assay Reagent B before incubating the plate at 
room-temperature for 5 minutes, protected from light. Finally, the plate was read at a wavelength 
of 750 nm in a spectrophotometer.  
 
F. Cholesterol Internalization in HLC – Immunocytochemistry 
1. Cell Treatment 
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 Non-corrected and corrected cells were plated in 3 wells of a 4-well chamber slide and 
differentiated to day one of stage three. The next day, one well from each cell line was treated 
with 5 µM Rosuvastatin in LPDS for 24 hours while the remaining two wells from each cell line 
stayed in stage three media. The following day, the well treated with Rosuvastatin was treated 
with 10 µg/mL DiI-LDL (Alfa Aesar) and 5 µM Rosuvastatin in LPDS for 24 hours. The 
remaining two wells from each cell line were treated with 5 µM Rosuvastatin in LPDS for 24 
hours. On the third day of treatment, with six hours remaining in the 24-hour period from the 
first well, 10 µg/mL DiI-LDL and 5 µM Rosuvastatin was added to the six hour well and the last 
well was left unchanged. The experiment was stopped when the first well reached 24 hours in 
DiI-LDL and Rosuvastatin incubation. Cells were continuously treated with Rosuvastatin as a 
way to upregulate the LDLR to maximize internalization of the DiI-LDL that was added in the 






Day 1: +RS 
Day 2: +DiI LDL 
            +RS 
Day 3: No change 
t=6h 
Day 1: No Change 
Day 2: +RS 
Day 3: +DiI LDL 
            + RS 
t=0h 
Day 1: No Change 
Day 2: +RS 
Day 3: No Change 
 
Figure 7 – Chamber slide set-up for immunocytochemistry 
 
2. Preparation for Imaging 
 Media was aspirated from all wells and replaced with 1X PBS +/+ for three washes. After 
the last wash, cells were fixed with 2% PFA (Electron Microscopy Sciences, Hatfield, PA) for 10 
minutes at room temperature. Cells were again quickly washed with 1X PBS +/+ before adding 
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VECTASHIELD Antifade Mounting Media with DAPI (Vector Laboratories, Burlingame, CA) 
and securing a glass cover on top. Cells were imaged at 20X magnification using Olympus 1X81 
fluorescence microscope (Center Valley, PA).  
 
G. HMG-CoA Reductase Activity in HLC 
1. Cell Treatment 
 Non-corrected and corrected cells were plated on 60 mm tissue culture dishes and 
differentiation began as described above upon reaching 75% confluency. Cells were 
differentiated to day one of stage three with treatment beginning the following day. Stage three 
media was replaced with LPDS and cells were incubated overnight. The following day, one dish 
from each cell line was collected as timepoint zero and the remaining dish from each cell line 
was treated with 10 µg/mL LDL in LPDS and incubated overnight and collected the following 
day.  
2. Cell Collection 
 Cell collection and analysis protocol was adapted from Kuzaj et al (Kuzaj et al., 2014). 
Cells were washed twice with ice-cold PBS +/+ then scraped and collected in additional ice-cold 
PBS +/+. Collected samples were centrifuged (3000 x g, 5 minutes) at 4°C and the pellets were 
resuspended in 120 µL lysis buffer (137.6 mM NaCl, 50 mM Tris/HCl, 8.7% Glycerin, 0.5 mM 
EDTA, 1% Protease Inhibitor, and 1% NP-40). Lysates were frozen for 1 hour at -80°C and 
clarified by centrifugation (8000 x g, 10 minutes) at 4°C. Supernatants were transferred to new 
tubes and a 10 µL aliquot was used to perform a DC protein assay (Bio-Rad).  
3. Sample Preparation 
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 50 µg total protein/sample were transferred to new microcentrifuge tubes and Q.S.’d to 
100 µL with enzyme reaction buffer (100 mM Potassium Phosphate Buffer, 0.1 mM EDTA, 50 
mM KCl, 10 mM DTT, 2.5 mM NADPH, 15 mM Glucose-6-phosphate, and 1 unit of Glucose-6-
phosphate dehydrogenase). Next, 50 µL of 200 µM HMG-CoA substrate in enzyme reaction 
buffer was added to reach a final volume of 150 µL. Samples were incubated at 37°C for 30 
minutes after which the reaction was stopped with the addition of 20 µL 6 M HCl. 300 µL of 
acetonitrile containing 10 µg/mL mevalonolactone-4,4,5,5,6,6,6-d7 (MVL-D7) was added and 
samples were vortexed for 5 seconds then centrifuged (13,000 x g, 10 minutes) at 4°C. 
Supernatants were stored at -80°C.  
4. Preparation for UPLC-MS/MS System 
 Samples were thawed and evaporated in a vacuum for 1.5 hours. Residues were dissolved 
in 50 µL HPLC-grade water/methanol/acetonitrile containing 0.5 M HCl (1:1:1 v/v) then vortex 
mixed for 10 seconds. Samples were centrifuged (13,000 x g, 10 minutes) and supernatants were 
transferred to autosampler vessels. 1 µL was injected into the ultra-performance liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS) system.  
5. Sample Protein Analysis 
 Samples were analyzed using western blot. 10 µg total protein/sample were loaded into 
4-15% Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad) and separated in 1X running 
buffer (10X Tris/Glycine/SDS buffer diluted in Milli-Q water) for 40 minutes at 200 V at room 
temperature. Gels were transferred onto methanol-activated PVDF membrane (Bio-Rad) in 1X 
transfer buffer at 100 V for 70 minutes at 4°C. Membranes were blocked in 3% non-fat milk in 
phosphate buffered saline with Tween 20 (PBST) and incubated in primary antibody overnight at 
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4°C (1:100 anti-HMG-CoA (Sigma-Aldrich) in PBS +/+ or 1:1000 anti-b-actin (Santa Cruz 
Biotechnology, Dallas, TX) in 3% non-fat milk in PBST. The following day, membranes were 
washed three times for five minutes in 1X PBST then incubated in secondary antibody for one 
hour at room temperature (1:5000 anti-mouse IgG HRP-linked (Cell Signaling, Danvers, MA) in 
3% non-fat milk in PBST. Afterward, membranes were again washed three times for five 
minutes in 1X PBST then developed with Clarity Max Western ECL Blotting Substrate (Bio-
Rad) and imaged on the Bio-Rad Imager. A table of antibodies used is available in the Appendix. 
 
H. ER Stress in iPSC and HLC 
1. Cell Treatment 
Non-corrected, corrected, and H1 iPSC or HLC were treated overnight with 5 µM 
Rosuvastatin excess sterols (10 µg/mL cholesterol and 5 µg/mL 25-Hydroxycholesterol) (Sigma-
Aldrich), or 5 µg/mL tunicamycin (4 hours) (Invitrogen) in 5% LPDS (Alfa Aesar, Tweksbury, 
MA). Tunicamycin is a chemical activator of the unfolded protein response and acted as a 
positive control to verify that this pathway is in fact inducible in our cells. Control cells were 
treated with DMSO overnight.  
2. Sample Collection and Analysis 
 Experiments were conducted and collected for mRNA or protein and analyzed as 
described previously but with markers for BiP and XPB1. Polymerase chain reaction (PCR) was 
carried out for spliced-XBP1 and XBP1 expression with PCR Supermix (Invitrogen). 10 µL of 
amplicons were added to 2 µL 6X Loading Buffer (Invitrogen) and run at 80 V for 60 minutes 
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using a 2% agarose gel (Bio-Rad). Gels were imaged using ChemiDoc MP Imaging System 
(Bio-Rad, Hercules, CA).  
 
I. Statistical Analysis 
 Experiments were conducted with a sample size of n=3 and data was analyzed using one-
way ANOVA with a post-hoc using Sidak’s multiple comparison test in GraphPad Prism 8 and 
expressed as mean ± SEM. Differences between control and treated samples were considered 






A. Rosuvastatin Upregulates LDLR Protein Levels and mRNA Transcripts in Non-Corrected and 
Corrected Cells 
 Non-corrected, corrected, and H1 iPSC or HLC were treated with Rosuvastatin or excess 
sterols in LPDS to analyze expression of LDLR protein and transcript levels in order to 
determine if the increase total LDLR protein observed earlier was a result of regulation at the 
transcriptional level. Excess sterols act independently of the LDLR and will enter the cell via 
non-receptor-mediated pathways, increasing the cholesterol content regardless of LDLR 
functionality. Rosuvastatin is an HMG-CoA Reductase inhibitor that will inhibit endogenous 
cholesterol synthesis. Figure 8a and Figure 8b show a significant upregulation in the expression 
of the immature LDLR protein in non-corrected iPSC and HLC that isn’t present in the corrected 
or H1 cells indicating that the CRISPR correction mediated the mutation present in the non-
corrected iPSC and HLC. For quantification, both immature, when present, and mature bands 




Figure 8 – LDLR protein expression in (A) iPSC and (B) HLC treated with Rosuvastatin (RS) or excess sterols 
(XS). ***p<.001, #p<0.05. 
 
Next, we looked at LDLR transcript levels to determine if the upregulation in immature 
LDLR in the non-corrected cells was the result of transcriptional regulation in the LDLR. qPCR 
analysis was conducted on iPSC and HLC treated with Rosuvastatin and excess sterols. Figure 
9a and Figure 9b show no significant difference across cell lines in the LDLR transcript levels. 
The statistical significance displayed represents the difference between treatments within each 
cell line. This indicates that the Rosuvastatin, as expected, upregulated LDLR transcript levels in 
NC, C, and H1 iPSC and HLC, but there was no statistically significant difference in the increase 
between each cell suggesting the increase seen at the protein level is not a result of an increase at 




Figure 9 – LDLR transcript levels in (A) iPSC and (B) HLC treated with DMSO (DM), Rosuvastatin (RS), 
or excess sterols (XS). *p<0.05, **p<0.01, ***p<0.001. 
 
B. LDLR Co-Localizes in ER in Non-Corrected HLC 
 Because we observed expression of majority immature LDL protein in the non-corrected 
cells, we looked at where the LDLR localized in the non-corrected HLC after Rosuvastatin 
treatment. As mentioned earlier, Calnexin is present in the ER and acts to retain misfolded 
proteins as one of its functions. Wheat germ agglutinin (WGA) binds to N-acetylglucosamine 
found in the plasma membrane and has been shown to bind to the hepatocyte cell membranes. 
HLC were treated with Rosuvastatin in LPDS overnight and confocal miscroscopy was used to 
determine localization of the LDLR protein. Figure 10a further confirms the upregulation of 
LDLR in Rosuvastatin-treated corrected and non-corrected HLC. We also included the images of 
the secondary control, labeled IgG, to show non-specific binding of the antibodies we used. 
Figure 10b presents the overlap of LDLR with calnexin or WGA where the overlap between the 
two channels is pseudo-colored yellow. This overlap was quantified and presented in Figure 
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10c. In the NC-HLC, we observed a significantly greater amount of LDLR overlap with calnexin 
when compared to LDLR overlap with WGA indicating a retention of the immature LDLR in the 
endoplasmic reticulum rather than its mature expression at the plasma membrane.  
 
 
Figure 10a – Localization of the LDLR in corrected and non-corrected HLC 
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Figure 10b – Overlap of LDLR with calnexin or WGA in NC-HLC and C-HLC 
 
 
Figure 10c – Quantification of LDLR overlap with calnexin or WGA in NC-HLC and C-HLC 
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C. Recovery of Predominantly Mature LDLR Protein Expression Restores Cholesterol 
Internalization in HLC 
 Upon confirming the predominant expression of the mature LDL receptor in the corrected 
cells, internalization of cholesterol was analyzed to determine if this was also mediated in the 
process. Cholesterol content was measured using the Thermo Fisher Amplex Red Cholesterol 
Assay Kit. HLC were treated with Rosuvastatin for 48 hours before methyl-b-cyclodextrin was 
added to remove any stored cholesterol (Francis et al., 1999). Cells were then incubated in LDL 
for six and 24 hours and analyzed via western blot. Figure 11 shows a significant increase in 
cholesterol internalization overtime in the corrected cells, but little to no change in 















Figure 11 – Cholesterol internalization in non-corrected and corrected HLC over 0, 6, and 24 hours.  
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To further confirm the increase in cholesterol concentration overtime was a result of the 
exogenously-introduced cholesterol, rather than the remnants of any endogenously-produced 
cholesterol, cells were treated with DiI-LDL and imaged. Results shown in Figure 12 further 
corroborate what was observed in the cells analyzed with the Amplex Kit. The corrected HLC 
display an internalization of DiI-LDL that increases with time from zero to 24 hours. In contrast, 
there is little internalization seen even at 24 hours in the non-corrected cells.  
 
 
Figure 12 – DiI-LDL internalization in non-corrected and corrected HLC over 0, 6, and 24 hours. 
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D. HMG-CoA Reductase Activity in HLC 
Next, HMG-CoA activity was determined using HPLC MS/MS. HMG-CoA Reductase 
catalyzes the reaction from HMG-CoA to Mevalonic Acid which equilibrates with the lactone 
form, Mevalonic lactone (MVL) at equilibrium (Kuzaj et al., 2014). Non-corrected and corrected 
HLC were treated with LPDS overnight before LDL in LPDS was added for a 24 hour treatment. 
Samples were prepared and analyzed used HPLC MS/MS along with protein samples collected 
for HMG-CoA protein expression. Mevalonic acid formation is one of the steps required in 
cholesterol synthesis, a process we would expect to be reduced in the corrected cells when they 
are able to obtain cholesterol from an exogenous source by using functional LDL receptors. We 
would, as a result, expect the concentration of MVL to decrease in the corrected cells, after the 
addition of LDL to the cell culture media, and the MVL concentration to stay the same in the 
non-corrected cells. Figure 13a shows no significant differences between cell lines in HMG-
CoA Reductase activity. Figure 13b also shows no significant differences between cell lines in 
HMG-CoA Reductase protein expression.  
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Figure 13 – (A) HMG-CoA Reductase enzymatic activity in non-corrected and corrected HLC as represented by the 
concentration of Mevalonic acid (MVL). (B) HMG-CoA Reductase protein expression in non-corrected and 
corrected HLC.  
 
E. Accumulation of LDLR in the ER Does Not Upregulate ER Stress Markers 
 Lastly, ER stress markers were analyzed to determine if the accumulation of the 
immature LDLR in non-corrected HLC induced the unfolded protein response, as has been 
suggested by other publications characterizing this disease (Jorgensen et al., 2000; Sorensen, 
Ranheim, Bakken, Leren, & Kulseth, 2006). Non-corrected, corrected, and H1 iPSC and HLC 
were treated with Rosuvastatin, excess sterols, or tunicamycin in LPDS and collected for protein 
expression and transcript level evaluation. Tunicamycin upregulates BiP expression, an early 
marker of ER stress, and was used as a positive control to verify that the UPR is inducible in all 
of our cells. BiP and spliced XBP1 expression was analyzed. Figure 14a and 14b show no 
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significant difference in BiP expression in neither iPSC or HLC. The significance displayed in 
the figure represent a difference between the treatments within each cell line, but not across the 
cell lines.  
 
 
Figure 14 – BiP expression in (A) iPSC and (B) HLC treated with DMSO (DM), Rosuvastatin (RS), excess sterols 
(XS), or tunicamycin (TM). *p<0.05, **p<0.01, ***p<0.001. 
 
 XBP1 is activated when unfolded proteins accumulate in the ER. IRE1 removes a 26-
nucleotide intron from unspliced XBP1 mRNA and leads to the production of a spliced product. 
Figure 15a and 15b show no significant differences between spliced XBP1 levels across cell 
lines. Splicing is upregulated in response to tunicamycin treatment within each cell line, but not 
across cell lines. We did observe upregulation in XBP1 splicing in H1 HLC in all treatments that 
was not present in the NC- or C-HLC. This difference may be due to cell type, the NC- and C-
HLC having differentiated from iPSC whereas the H1-HLC were differentiated from ESC. ER 
stress and the UPR is not the same in all stem cells and requires further investigation to 
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determine differences that may be present between different types of stem cells (Yang, Cheung, 
Tu, Miu, & Chan, 2016).  
 
 
Figure 15 – Spliced XBP1 in (A) iPSC and (B) HLC treated with DMSO (DM), Rosuvastatin (RS), excess sterols 
(XS), or tunicamycin (TM). *p<0.05, **p<0.01, ***p<0.001.  
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IV. CONCLUSION  
 We observed an increase in the immature LDLR in NC cells that was mediated by 
CRISPR correction. This marked increase in the immature LDLR was not the result of increased 
regulation at the transcriptional level as we showed in our study. One point to consider here is 
how PCSK9 regulation plays a role and whether this would indeed affect LDLR at the 
transcriptional level. We did not look at PCSK9, but it would be important to determine if it is 
upregulated as a result of the statin treatment as has been suggested by the literature. From our 
results, we can presume that while PCSK9 may be upregulated, it is not upregulated in a 
significant manner that further compounds the expression of the LDL receptor. If PCSK9 was 
upregulated in a significant manner, then we can assume that it would degrade the small amount 
of functional LDL receptors present in NC cells and this would correlate with increases in LDLR 
at the transcriptional level, an increase that we did not observe.  
 We showed a co-localization of the LDLR with the ER in non-corrected HLC that was 
not seen in the corrected HLC, where the LDLR co-localized instead with the cell membrane. 
We saw significantly greater LDLR overlap with ER resident, calnexin, when compared to 
LDLR overlap with the plasma membrane further confirming the retention of the LDLR in the 
ER in the mutated cells and the mediation of this through CRISPR correction. This corrected co-
localization was also further corroborated with our cholesterol internalization assays showing 
increased internalization with time with the corrected HLC whereas minimal cholesterol was 
internalized in the non-corrected HLC, expressing very little mature LDL receptor. The small 
amount of internalized cholesterol observed may represent non-receptor mediated pathways of 
cholesterol internalization, such as pinocytosis, in addition to the receptor-mediated pathway 
resulting from the few functional, mature LDL receptors.  
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 Regulation of the LDL receptor is dependent on the careful balance that exists between 
the two sources of cholesterol, de novo synthesis and receptor-mediated endocytosis. We 
believed that HMG-CoA reductase activity would decrease in corrected HLC after the addition 
of LDL-C as a way of homeostatic feedback. The logic being, if cells were starved of exogenous 
cholesterol by culturing in lipoprotein deficient serum media, HMG-CoA reductase activity 
would increase to synthesize endogenous cholesterol. Then upon addition of exogenous LDL-C, 
HMG-CoA reductase activity would decrease to balance out the amount of endogenously-
produced cholesterol and the cholesterol taken up through the receptors and that this decrease 
would not be observed in the non-corrected cells, due to low numbers of functional LDLR. This 
is not what we observed in our study and this represents a limitation here. In both corrected and 
non-corrected HLC, HMG-CoA reductase activity slightly, but not significantly, increase upon 
addition of LDL-C into the culture media. This leads us to question if our experimental 
conditions were appropriate for this analysis. Soufi et al. described the use of LPDS as 
physiologically irrelevant due to this abnormal upregulation of cholesterol metabolism genes by 
LPDS (Soufi, Ruppert, Kurt, & Schaefer, 2012). The entire duration of the treatment was 
conducted with LPDS media, both during starving the cell of exogenous cholesterol and 
introducing exogenous cholesterol. Soufi’s finding suggests that because of LPDS’s ability to 
upregulate cholesterol metabolism genes, they are upregulated to a magnitude that is not 
significantly affected by the addition of exogenous cholesterol. So perhaps, our experiment was a 
little counterintuitive in nature as we were upregulating cholesterol metabolism genes throughout 
the duration of the treatment, which is not physiologically representative, and in turn we were 
not able to see the true activity of HMG-CoA reductase as a regulatory portion of cholesterol 
homeostasis. To verify this, we can conduct a quick experiment to determine the effects of the 
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LPDS by culturing cells in basal media or basal media supplemented with LPDS and collect for 
mRNA or protein expression of cholesterol metabolism genes. Moving forward, it would be 
important to consider this experiment with some minor changes. One mainly being the duration 
of the treatment being conducted in a media that starves cells of exogenous cholesterol without 
simultaneously upregulating cholesterol metabolism genes. We could use a culture medium that 
doesn’t necessarily starve cells of exogenous cholesterol and add exogenous LDL-C overtime 
and measure HMG-CoA reductase activity that way.   
 The unfolded protein response is activated as a result of protein accumulation in the ER. 
Publications have shown that proteins associated with the UPR are upregulated in Class II LDLR 
mutants (Jorgensen et al., 2000; Sorensen et al., 2006). Upon seeing expression of the immature 
LDLR in non-corrected iPSC and HLC and the co-localization of the LDLR with the ER in non-
corrected HLC, we looked to see if this induced ER stress and activated the UPR. Our findings 
show that ER stress markers, BiP and spliced XBP1, are not upregulated in statin-treated non-
corrected iPSC or HLC despite predominant expression of the immature LDLR. One thing to 
note is the conditions of the experiments performed in the publications that did report ER stress 
in Class II LDLR mutant cells. In Sorenson et al., cells were transfected with a constitutively-
expressing mutant which may have resulted in levels of accumulation and in turn upregulated 
levels of ER markers many folds higher than what would occur in a true physiological 
environment. By using patient-derived mutant cells, we present a response that is more likely to 
be true in a physiological environment, but we cannot conclude that no ER stress is occurring. 
There still remain two other pathways and a number of proteins that we did not look at that need 
consideration before any such conclusion can be made. In the future, it is important to look at the 
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remaining two pathways, PERK and ATF6, and downstream proteins to provide a better overall 
picture of what is happening in the ER as a result of the protein accumulation.  
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V. FUTURE WORK 
A. Bioartificial Liver 
There remains a significant shortage of available livers to provide a cure for those suffering 
from FH. In addition, organ allocation protocols, cost of organ transplant, and rejection of donated 
organs present an additional obstacle further impeding FH patients from what may be their only 
real cure. Here, we have presented the feasibility of not only correcting mutant FH cells, but 
differentiating them into hepatocyte-like cells with restored cholesterol homeostasis that can be 
utilized in a number of applications. One such application may be the use of these corrected HLC 
in a decellularized liver matrix that can be isolated from the FH patients themselves or from organ 
donors with diseased livers that retain a functional matrix. Ott et al. presented the methodology for 
perfusing a decellularized heart matrix with neonatal cardiac cells in 2008 (Ott et al., 2008). The 
extracellular matrix (ECM) supplies cells with growth factors and signals that promote 
proliferation, regeneration, and organization of cells that is lacking in vitro. Of course there remain 
a number of steps before this can be fully executed. In Ott et al. only one injection site was used 
to perfuse the matrix with cardiac cells which resulted in only 2% pump function. This can be 
potentially mediated by introducing multiple injection sites to provide a more widespread 
perfusion of cells. For the liver specifically, it is also important to introduce non-parenchymal cells 
in order to provide the organ with all necessary cell types to perform the many functions of the 
liver. These cells may include sinusoidal endothelial cells, Kuppfer cells, and hepatic stellate cells 
(Kmiec, 2001). This application would give use to livers that may not be functional or healthy 
enough to be transplanted due to presence of disease or other damage, but retain a functional ECM 
that provides a physiologically-derived blank canvas that can be put to use. Another benefit of this 
application is the use of autologous cells in order to reduce possibility of rejection. As we have 
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presented in this work, patient-derived cells would be isolated, corrected, and differentiated into 
mature hepatocytes before perfusion into a donated liver matrix.  
 
B. Use in Personalized Drug Therapy 
 iPSC present an attractive and physiologically relevant method for developing new drugs 
and evaluating cytotoxicity. In addition, patient-derived iPSC provide a more intimate overview 
of the disease affecting each patient, specifically. Often, FH patients are prescribed a 
combination treatment protocol consisting of lifestyle changes, statin therapy, and lipoprotein 
apheresis. Regardless of similarity in the disease, patient response to treatments differ. HoFH 
patient-derived iPSC can be differentiated into HLC and used to test different combinations of 
treatment protocols. For example, there exist a wide range of statin drugs so testing the efficacy 
of each one on patient-derived cells can provide a more rapid and efficient method for 
determining the optimal drug and dose specific to that patient. This saves time and provides 
optimal treatment for the patient quicker than monitoring cholesterol levels in relation to each 
attempted drug protocol.  
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